On the 11th, AprilBio shares hit the upper price limit early in trading. Buying gathered on news that a phase 2 clinical trial of an atopic dermatitis treatment succeeded.
As of 9:49 a.m. on the KOSDAQ market, AprilBio was trading at 69,200 won, up 15,900 won (29.83%) from the previous session.
On the previous day, AprilBio's partner Evommune said it successfully completed a phase 2a clinical trial of "APB-R3" for atopic dermatitis. Administration of APB-R3 showed a statistically significant reduction in EASI (Eczema Area and Severity Index) compared with placebo. APB-R3 is a subcutaneous injection (SC) formulation and is set to enter a phase 2b trial.
Wi Hae-ju, a researcher at Korea Investment & Securities Co., said, "The clinical success of R3 owed much to AprilBio's SAFA platform," adding, "Expectations are high for the next-generation drug candidates with SAFA binding released by AprilBio and for the acceleration of technology transfer for the REMAP platform." The target price of 100,000 won was maintained.